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Abstract:  3 
Background: Previous evidence demonstrated that serum leptin correlated with appetite with, 4 
but not without, modest exercise.  5 
Aim: The present experiments investigated the effects of exogenous adrenaline and α/β 6 
adrenoceptor blockade in combination with moderate exercise on serum leptin concentrations, 7 
appetite/satiety sensations and subsequent food intake in obese women.  8 
Methods: Ten obese women [(mean ± SEM), age: 50 (1.9) y, body mass index: 36 (4.1) 9 
kg/m2, waist: 104.8 (4.1) cm] participated in two separate, double-blind randomised 10 
experimental (EXP) trials. EXP-1: moderate exercise after α/β adrenergic blocker (labetalol, 11 
100mg orally) vs. moderate exercise plus placebo; EXP-2: adrenaline infusion for 20 min vs. 12 
saline infusion. Appetite/satiety and biochemistry were measured at baseline, pre- and 13 
immediately post-intervention, 1-h post-intervention (i.e., before dinner). Food intake was 14 
assessed via ad libitum buffet style dinner. 15 
Results: No differences were found in appetite/satiety, subsequent food intake, or serum 16 
leptin in any of the studies (EXP-1 or EXP-2). In EXP-1, blood glucose was higher (p < 0.01) 17 
and plasma FFA lower (p = 0.04) vs. placebo. In EXP-2, plasma FFA (p < 0.05) increased 18 
after adrenaline vs. saline infusion.  19 
Conclusion: Neither inhibition of exercise-induced adrenergic activity by combined α/β 20 
adrenergic blockade, nor moderate increases in adrenergic activity induced by intravenous 21 
adrenaline infusion affected acute appetite regulation. 22 
Key words: appetite regulation, adrenaline infusion, adrenergic blockade, moderate exercise, 23 
obesity 24 
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Introduction 27 
Obesity, is the most prevalent single disease in the world (ICD.10 code E.66), with 28 
more than 2.1 billion adults overweight (Ng et al., 2013). Better understanding of the 29 
mechanisms that regulate food intake, energy expenditure (EE), and energy balance, is critical 30 
for the prevention and management of obesity. Physical activity has been implicated in 31 
appetite and body mass regulation; appetite also seems to be ‘coupled’ to body weight control 32 
in individuals undertaking moderate physical activity (Shook et al., 2015). While physical 33 
activity tends to increase food intake (Westerterp et al. 2015), habitual exercisers are able to 34 
closely match food intake to EE (Martins et al., 2008); however, the mechanism underpinning 35 
the coupling between physical exercise and food intake regulation has yet to be explained.  36 
In experimental rodent models and in cases of congenital obesity, leptin is a key 37 
regulator promoting satiety (Farooqi et al., 2009). In humans, leptin concentration is closely 38 
correlated to total fat mass (Considine et al., 1996) and physical activity strongly predicts 39 
circulating leptin concentrations independently of body fat mass suggesting a plausible role of 40 
physical activity in leptin sensitivity (Chu et al., 2001). Raised circulating leptin 41 
concentrations do not appear to prevent overeating in obese humans; who are considered 42 
‘leptin resistant’ (Lean et al., 2016). Indeed, most models of diet-induced obesity in rodents 43 
have presented evidence that obesity causes central and peripheral leptin resistance whereby 44 
anorexigenic/orexigenic neurons fail to signal satiety in response to high circulating leptin 45 
(Morris and Rui, 2009). Leptin’s transport across the blood brain barrier is also reduced 46 
concurrently with increasing adiposity (Banks and Farrell, 2003). As human obesity is 47 
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associated with impaired appetite control, this implies that other factors may influence the 48 
anorexic effects of leptin. 49 
Several studies have demonstrated the acute regulation of circulating leptin turnover 50 
by adrenergic agents and catecholamine (Keller et al., 2005; Scriba et al., 2000) and the role 51 
of endogenous catecholamine in the hypothalamic paraventricular nucleus (PVN) has been 52 
related to eating or satiety (Wellman, 2000). Activation for example, of α2-adrenoceptors in 53 
the PVN enhances eating, whereas activation of α1-adrenoceptors inhibits eating (Wellman et 54 
al., 1993). Moreover, an acute effect of elevated adrenaline levels on enhanced leptin 55 
transport into the brain through activation of predominantly α1-adrenoceptors was found in 56 
rats (Banks et al., 2001). A link between obesity, inactivity and raised circulating leptin 57 
concentrations has been clearly demonstrated (Chu et al., 2001), which suggests that high 58 
circulating leptin concentrations are ineffective in regulating appetite and body mass when 59 
physically inactive. Studies in lean and obese rats suggested that acute and chronic exercise 60 
improved the antiorexigenic action of leptin, as well as hypothalamic leptin signalling 61 
(Krawczewski et al., 2011; Ropelle et al., 2010).  62 
We also reported an association between circulating leptin and appetite suppression in 63 
obese individuals, but only following an acute bout of moderate-intensity exercise (Tsofliou 64 
et al., 2003). These studies support a role of exercise in mediating the action of leptin on 65 
appetite regulation in the short term. As even light exercise is known to produce a marked 66 
stress-response in sedentary individuals (Salvadori et al., 2003), the increase in 67 
catecholamines that normally accompanies such a response might be responsible for the 68 
coupling of leptin and appetite. Adrenaline may facilitate leptin transport into the brain 69 
through stimulation of α-adrenoceptors located at the blood side of the blood brain barrier 70 
(Banks, 2001). The purpose therefore of the current study was to investigate the effects of 71 
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increased circulating adrenaline concentrations by exogenous intravenous administration, and 72 
the effects of moderate exercise performed during α/β-adrenoceptor blockade, on our primary 73 
outcomes, appetite-satiety measures and on subsequent food intake in obese women. We also 74 
investigated the impact of these interventions on biological markers such as circulating leptin, 75 
glucose and free fatty acids (FFA) concentrations, using the association between serum leptin 76 
and appetite/satiety sensations as an indirect index of leptin sensitivity. 77 
 78 
Material and methods 79 
This study is reported according to the CONSORT guidelines (Schulz et al., 2010) 80 
(Figure S1 and Table S1 in Supplementary Files) 81 
Participants   82 
Ten (n=10) obese but otherwise healthy, premenopausal women (Table 1) gave 83 
written informed consent to participate in the study, which was conducted in accordance with 84 
the declaration of Helsinki. The sample size used in this study was based on the primary 85 
outcomes of interest such as appetite ratings and ad libitum intake. Using a paired design and 86 
a power of 0.8, a minimum of 9 participants would be needed to detect a 10 mm difference in 87 
postprandial ratings and to detect a 100 kcal difference in ad libitum EI (Lara et al., 2010; 88 
Horner et al., 2014). The protocol was approved by the the Glasgow Royal Infirmary 89 
Research Ethics Committee, (01HU009, 02HU002). All participants were in good physical 90 
and mental health with normal blood pressure (≤ 140 / ≤ 90 mmHg), non-smokers, on no 91 
medication known to affect appetite, not known to be anaemic or hyperlipidemic and not on a 92 
special diet. Following eligibility screening and familiarisation with methodological 93 
procedures, using a double-blind, cross-over design, participants were randomised to 94 
intervention for each experiment (EXP-1 & EXP-2) using an online random number generator 95 
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(http://www.randomization.com). The order of the trials for each experiment was randomised 96 
separately. There was an interval of at least seven days between trials. In EXP-1 (exercise 97 
with either α/β-adrenoceptor blocker or placebo) all 10 eligible participants took part in the 98 
study procedures and data analysis while in EXP-2 (adrenaline vs. saline infusion) results are 99 
presented from nine participants; one participant did not continue after EXP-1. 100 
Concealed treatment allocation was implemented; a person, unrelated to the trial 101 
prepared the treatment allocation using sealed opaque envelopes. Both participants and 102 
researchers evaluating the impact of the experiments were blinded to treatment. Intervention 103 
agents were dispensed at each visit by two members of the staff not involved in the study.  104 
 105 
Experimental design and procedures 106 
Adrenaline was infused (MacCarthy et al., 1983; Centers for Disease Control, 2007), 107 
raising circulating adrenaline levels to those typically seen during moderate exercise (Lean et 108 
al., 1996). On a separate occasion, labetalol, which blocks α1-, β1- and β2-adrenoceptors, 109 
MacCarthy et al., 1983; McLoughlin et al., 1992) was administered prior to moderate 110 
exercise. Participants visited the laboratory on four occasions to participate in four acute 111 
interventions with an interval of at least seven days between trials (Figure 1); EXP-1: 112 
moderate-intensity exercise with either α/β-adrenoceptor blocker or placebo, and EXP-2: 113 
adrenaline infusion vs. saline infusion. Participants kept diet and physical activity records for 114 
two days preceding the first experimental trial. These food and activity patterns were 115 
replicated before all subsequent trials. Household measures (i.e., glasses, cupfuls, 116 
tablespoons, slices, etc.) were used to quantify food and fluid consumption. For each 117 
experiment, participants visited the laboratory approximately 5-h after a standard lunch and 118 
this time duration was standardised within subject. Upon arrival at the laboratory, weight, 119 
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waist and hip circumference were measured using calibrated scales and inextensible tapes 120 
with bone landmarks for anthropometry (Centers for Disease Control, 2007). Body fat 121 
percentage was predicted from waist (Lean et al., 1996). Arterialised-venous blood samples 122 
(McLoughlin 1992) were collected from an 18G indwelling catheter placed by percutaneous 123 
puncture into a vein on the dorsum of a heated hand and a baseline sample (-60 min) was 124 
taken. Serial blood samples (10 ml) were then drawn at 0, 20 and 80 min. Following each 125 
blood sample, participants completed a set of self-rating 100-mm visual analogue scales for 126 
hunger, desire to eat, prospective food consumption, satiety and fullness (Stubbs et al., 2000). 127 
Throughout each trial, participants were seated in a comfortable environment watching food-128 
related digital versatile DVDs for 60 min. Food-related DVDs were intended to direct 129 
participants’ attention towards food and eating, to stimulate a familiar form of home 130 
entertainment which might reduce anxiety and eating restraint (Bellisle et al., 2001). 131 
After watching the food-related DVDs, participants took part in one of the following 132 
interventions on each of the four study-days; EXP-1: 60 min prior to each of the two exercise 133 
trials, participants were given either 100mg labetalol (Generics UK)] or placebo (calcium 134 
carbonate). Then the participants were required to walk at a moderate pace (5km/h) on a 135 
motorised treadmill for 20 minutes. This is in line with a previous study of our group that 136 
found acute leptin coupling with appetite/satiety measures after a bout of moderate intensity 137 
exercise in obese women (Tsofliou et al., 2003).  138 
In EXP-2: a single dose of either adrenaline hydrochloride (i.e., a 1:10,000) diluted in 139 
normal saline, or normal saline, was infused intravenously at a rate of 12.5ng min/kg ideal 140 
body mass, via a pump for 20 min (Webber et al., 1994), to yield a plasma level not exceeding 141 
1nmol/L. This dosage ensures that the plasma catecholamine concentration will not exceed the 142 
level typically measured following moderate-intensity exercise (Gustafson et al., 1990). This 143 
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dosage aimed to maintain catecholamine concentrations similar to the levels attained by the 20 144 
min of moderate exercise (McLoughlin et al. 1992). The DVD was switched off for 20 min 145 
during each infusion. 146 
Following each intervention, participants continued watching food-related DVDs for 147 
another 1-h. They were then offered a buffet-type dinner comprising 11 food items: chicken 148 
breast roasted (200g), baby potatoes roasted (160g), onion stuffing (60g), boiled peas (126g), 149 
boiled carrots (116g), boiled corn (118g), tuna cucumber sandwich (176g), chicken and salad 150 
sandwich (178g), banana (100g), 2 apple pies (120g), potato crisps (26g) and orange juice 151 
(500ml), and were asked to eat as much as they wanted within 1h. Each person’s selection 152 
from the buffet dinner was analysed for energy intake and macronutrient content using a 153 
computerised version of McCance and Widdowson's (revised by Holland et al., 1993) food 154 
composition tables and elative energy intake (REI) was calculated for both exercise trials in 155 
EXP-1 as energy intake minus the energy cost of the exercise (Douglas et al., 1982). 156 
Rating of perceived exertion (breathlessness and leg exertion) (Borg, 1982) and heart 157 
rate (HR) (Polar Sport Tester, Polar Electro Oy, Finland) were recorded every 10 min during 158 
the moderate exercise and the infusion interventions. For EXP 1, expired gas was collected in 159 
Douglas bags for 5 min at rest, and thereafter 1 min collections were obtained every 10 min 160 
during the moderate exercise interventions. Expired gases were analysed within 5 min of 161 
collection for [ 2O ] (Servomex 570A, East Sussex, UK) and [ 2CO ] (Servomex 1400 B4, East 162 
Sussex, UK), volume (dry gas meter, Harvard Apparatus Ltd., Hertfordshire, UK) and 163 
temperature (C6600 10-Channel Microprocessor, Comark, Hertfordshire, UK). Barometric 164 
pressure was measured using a standard mercury barometer. Oxygen uptake ( 2OV ), carbon 165 
dioxide production ( 2COV ) and respiratory exchange ratio (RER, i.e. 2OV / 2COV ) were 166 
subsequently evaluated and the percentages of fuel oxidation were determined. Energy 167 
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expenditure (kcal·min-1) (Ravussin et al., 1985) and the rates of fat and carbohydrate 168 
oxidation (g·min-1) (Alkahtani et al., 2014) were calculated by standard equations: Energy 169 
expenditure = {4.686 + [(RER - 0.707) / 0.293] x 0.361} x VO2; Fat oxidation = (1.67 x VO2) 170 
- (1.67 x VCO2); Carbohydrate oxidation = (4.55 x VCO2) - (3.21 x VO2). 171 
 172 
Blood treatment and analyses 173 
Venous blood was collected into K3EDTA vacutainers for the measurement of blood 174 
glucose, plasma free fatty acids (FFA) (colorimetric method, Boehringer Mannheim 175 
Biochemica, London, UK) and into clot activator vacutainers for serum leptin measurement. 176 
Duplicate aliquots (400 µl) of whole blood from the K3EDTA tube were rapidly 177 
deproteinised in 800 µl of 0.3 mol.l-1perchloric acid; following centrifugation the supernatant 178 
was used for the measurement of glucose (Maughan, 1982). Plasma supernatant was separated 179 
and plasma (500 µl) was mixed with 50 µl EGTA-glutathione and stored at -70°C for 180 
subsequent determination of adrenaline and noradrenaline (Forster, 1999). The remaining 181 
plasma was stored at -20°C and later used for the measurement of FFA (colorimetric method, 182 
Boehringer Mannheim Biochemica, London, UK). Blood collected into the clot activator 183 
vacutainer was allowed to clot for 10 min. Following centrifugation, the serum was stored at -184 
70°C and subsequently analysed for leptin by radioimmunoassay. 185 
 186 
Statistical analysis 187 
Statistical analyses were carried out with IBM SPSS v22 for Windows. To assess the 188 
impact of interventions statistical analysis of the data was carried out using General Linear 189 
Model (GLM) with repeated measures followed by pairwise analysis with Bonferroni 190 
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adjustment. Results are presented as estimated marginal means ± SEM. Correlation analysis 191 
was also carried out between serum leptin concentrations and appetite measures (for each time 192 
point separately) and adiposity indices. Statistical significance was taken as p < 0.05. 193 
 194 
Results   195 
Effects on self-reported appetite-satiety ratings and subsequent dietary intake 196 
Profiles of hunger, desire to eat, prospective food consumption (PFC), fullness and 197 
satiety throughout each intervention in both experiments are shown in Figures 2a and 2b. In 198 
both EXP-1 and EXP-2, a main time effect was observed in all appetite-satiety measures and 199 
there were no significant differences on appetite/satiety measures between interventions.  200 
In EXP 1: General Linear Model showed a significant time effect for huger ratings (p 201 
= 0.003), satiety, desire to eat, and for PFC ratings (p = 0.002). No differences were found 202 
over time in prospective food consumption or fullness ratings (Figure 2a). In EXP-2: there 203 
was a significant time effect for hunger, satiety, fullness, PFC and for the desire to eat (p < 204 
0.001). 205 
Self-selected food intake at dinner did not differ significantly between trials in either EXP-1 206 
or EXP-2 (Table 2). 207 
 208 
Effects on biochemical measures in both experiments 209 
In EXP-1: There was no effects of intervention (p = 0.6) and time by intervention 210 
interaction (p = 0.4) for serum leptin. Significant differences were found in blood glucose and 211 
plasma FFA between the two moderate exercise interventions. Blood glucose concentrations 212 
were significantly higher and plasma FFA were significantly lower for 1h after the Moderate 213 
exercise plus α/β blocker intervention compared to Exercise plus placebo (Table 3).  214 
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In EXP-2: There was no significant difference on serum leptin concentrations and blood 215 
glucose concentrations between the adrenaline and the saline infusions or over time, 216 
throughout the trials (p > 0.05). Plasma concentrations of FFA were significantly higher 217 
immediately after the adrenaline infusion compared to saline infusion (FFA p = 0.032). In 218 
addition, plasma NA concentrations showed a borderline significant difference between 219 
treatments (Table 4).   220 
Baseline serum leptin concentrations correlated significantly with body mass index (BMI 221 
(kg.m-2), fat mass (FM (%) and waist circumference (BMI r = 0.78, p = 0.01, FM r = 0.63, p= 222 
0.04, Waist r = 0.71 p = 0.02). No significant associations were found between serum leptin 223 
concentrations and appetite-satiety measures at any time point in the two experiments (p > 224 
0.05).  225 
Physiological responses to treadmill walking and to adrenaline infusion  226 
HR, perceived breathlessness and leg-tiredness during the moderate exercise and the 227 
infusion interventions are show in Table 5; there was no significant difference in HR between 228 
trials in either EXP-1 or EXP-2 (Table 5). The average energy expenditure (EE) of 229 
participants was 136 kcal (± 30) and 128 (± 40) in exercise plus placebo and exercise plus α/β 230 
blocker respectively; the EE was not significantly different between exercise trails. In both 231 
EXP-1 and EXP-2, oxygen uptake ( 2OV ), carbon dioxide production ( 2COV ), respiratory 232 
exchange ratio (RER) and fuel oxidation rates were not significantly different between trials ( 233 
Table 6).   234 
 235 
Discussion 236 
In the current study, we examined the effects of exogenous adrenaline and α-/β-237 
adrenoceptor blockade in combination with moderate exercise on serum leptin concentration, 238 
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appetite/satiety sensations and food intake in obese women. It was envisaged that this 239 
approach would allow us to identify whether adrenergic stimulation mediates the central 240 
effect of leptin on appetite regulation. The novel result of the current study is that moderate 241 
manipulation of adrenergic activity via adrenaline infusion or α/β-adrenoceptor blockade 242 
using 100 mg labetalol during moderate intensity exercise was not found to affect post-243 
exercise appetite/satiety sensations and subsequent energy intake in obese women. 244 
Previous studies have shown impaired catecholamine responses to physical exercise in 245 
obese individuals (Salvadori et al. 2003). In the current study, plasma noradrenaline 246 
concentration increased to 2.3nmol∙l-at the end of the adrenaline infusion1 (only borderline 247 
significance was found though), typical of the suppressed levels found during exercise in 248 
obesity; substantial variation was reported in noradrenaline concentration during intense or 249 
exhaustive exercise in obese, young individuals (from 4.28 to 5.9 nmol∙l-1) (Zouhal et al. 250 
2013). HR tended to increase towards the end of the adrenaline infusion (82b.min-1) at similar 251 
levels with previous adrenaline infusion studies in obese women (Walsh et al. 1998) but we 252 
did not observe significant differences; plasma FFA reached concentrations of 1.09mmol∙l-1, 253 
which is indicative of adrenaline-stimulated lipolysis (Webber et al. 1994). We were not able 254 
to determine post adrenaline infusion values of circulating adrenaline concentrations due to 255 
unresolved peaks co-eluting with adrenaline. However, the plasma FFA profiles would be 256 
consistent with responses to plasma adrenaline concentrations above 0.6nmol∙l-1 (~0.8nmol∙l-1 257 
during 20 min of 12.5ng per kg IBW per minute adrenaline infusion), a level that would 258 
stimulate lipolysis (Webber et al. 1994). 259 
Catecholamines have long been implicated in appetite regulation as clinical appetite 260 
suppressants in obese patients (Lean and Finer, 2006) and it is demonstrated that they exert 261 
regulatory effects upon the expression of mRNA leptin and circulating leptin concentrations 262 
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(Ricci and Fried, 1999). The current study, is the first study though to investigate the role of 263 
short-term increases in adrenergic activity in the acute appetite response following exercise in 264 
humans. It was observed that 20min of adrenaline infusion did not affect acute appetite or 265 
serum leptin concentration and leptin concentrations did not also change after 20min of 266 
moderate intensity exercise. This is in agreement with others that found decreases in leptin 267 
only after prolonged moderate intensity exercise in trained men (Zaccaria et al. 2013) and 268 
overweight women (Tiryaki-Sonmez et al., 2013) or a delayed leptin reduction in active 269 
individuals within a 24h timeframe post-exercise (King et al., 2015). Notably, exercise-270 
induced noradrenaline increase, but not other biochemical factors (i.e. cortisol or FFA), was 271 
suggested to account for the reduction in post-exercise circulating leptin (Zaccaria et al. 272 
2013). However these studies did either not measure subsequent effects on appetite/satiety 273 
feelings post exercise or found no compensatory appetite response (King et al., 2015). As the 274 
exercise-induced appetite regulatory response, both hormonal and behavioural, might diverge 275 
in the presence of obesity (Heden et al. 2013) whether there is interplay between adrenergic 276 
activity, leptin response and appetite expression after exercise remains to be clarified utilising 277 
different modes of exercise in individuals with different body weights.  278 
Furthermore, research in physical exercise and appetite regulation has shown that 279 
single bouts of exercise might suppress the orexigenic ghrelin while simultaneously elevating 280 
anorexigenic signals peptide YY (PYY), glucagon-like peptide-1 (GLP-1), cholecystokinin 281 
(CCK) and pancreatic polypeptide (PP) (Zouhal et al.2019). These observations have been 282 
reported mainly in lean, physically active males while evidence in females and particularly 283 
in individuals with obesity is sparse and contradictory. It is also suggested that exercise 284 
training in women with obesity might influence the regulation of food intake via improved 285 
leptin sensitivity (Martins et al., 2013). New evidence from animal studies indicates that 286 
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leptin might enhance the effects of gut satiety hormones highlighting the importance of 287 
interactions among the feeding-related hormones which probably lead into an integrated 288 
anorectic signal (Akieda-Asai et al., 2014). Future studies need to measure leptin in 289 
conjunction with the other appetite-regulating peptides (acylated ghrelin,  PYY,  GLP-1, CCK 290 
and PP) to enable a better understanding of how exercise-induced responses to appetite-291 
regulating hormones might differ in obesity (Dorling et al., 2018).    292 
With regard to the effect of adrenaline infusion on acute appetite control in obese 293 
women, previous studies reported reduced circulating leptin concentrations after 60min of 294 
adrenaline infusion (0.010µg/kg fat free mass/min) suggesting that a decrease in obesity-295 
related leptinemia could stimulate a compensatory appetite response but this was not assessed 296 
(Couillard et al., 2002). The lack of any significant adrenaline-induced decrease in serum 297 
leptin concentrations in the present study may be due to the shorter period of adrenaline 298 
infusion compared to previous studies which found reduced circulating leptin levels after 299 
infusions of 60 to 180min (Couillard et al., 2002). Secondly, the large variability in leptin 300 
response to adrenaline previously observed in human obesity, i.e low- and high-leptin 301 
responders, could account for the present unchanged leptin concentrations during adrenaline 302 
infusion and could indicate a potential heterogeneity in leptin sensitivity among obese 303 
individuals (Couillard et al., 2002). It is possible that adrenaline-induced changes in leptin 304 
could induce changes in appetite/satiety sensations and food intake in the short-term, but 305 
additional work is necessary to understand the complexity of this physiological mechanism, 306 
the timeframe of its action and whether there are differences in regulation of appetite and food 307 
intake between low- and high-leptin responders to adrenaline. 308 
The current study was not able to reproduce the association between leptin and 309 
appetite sensations that was found in our earlier study (Tsofliou et al., 2003). There was no 310 
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evidence for a difference in energy intake (EI) 1h after the moderate exercise with placebo 311 
(average 813kcal) compared to α/β-adrenergic blockade (average kcal 900) (p = 0.2). When 312 
the relative EI (REI) was additionally calculated for the exercise trials, no difference in REI 313 
incurred between exercise with placebo (677 kcal) and exercise with α/β-adrenergic blockade 314 
(772 kcal). Previous data from walking studies reported no compensatory response in absolute 315 
EI in lean and obese individuals and either no changes in relative EI or a significant decrease 316 
when the median energy deficit of exercise was around 335kcal (Schubert et al., 2013). The 317 
present findings indicate that α/β-adrenergic blockade was not able to induce a different 318 
appetite response to exercise with placebo and did not trigger a compensatory response in EI 319 
and appetite sensations after an acute exercise-induced energy deficit. These findings however 320 
were derived from a small sample and require further verification. 321 
In the present study, labetalol 100mg resulted in a lower plasma FFA concentration 322 
immediately after and 1h  after moderate exercise (0.49nmol.l-1, 0.59nmol.l-1 respectively) 323 
compared to placebo (0.74nmol.l-1, 0.73nmol.l-1 respectively) possibly by blocking the β-324 
receptor mediated lipolysis (Ladage et al., 2013). The α/β-adrenergic blockade also induced a 325 
significant increase in post-exercise blood glucose concentration (4.9mmol.l-1) compared to 326 
placebo (4.5mmol.l-1). These results are supported by earlier studies (Hartling, 1980). 327 
However, they are disputed by recent reports suggesting that β-blockers differ in terms of 328 
their mechanism of action and their effects on glucose and lipid metabolism with respect to 329 
their molecular pharmacological mechanisms (Ladage et al., 2013); and particularly, 330 
nonvasodilating β-blockers are associated with even a worsening of glycemic and lipidic 331 
control at rest (Fonseca, 2010). With regard to α- blockade, 100mg labetalol, did not produce 332 
significant differences in resting and post-exercise HR. This is in line with previous studies 333 
showing that labetalol at doses of 100, 200 and 400mg did not alter resting HR compared to 334 
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placebo in healthy males (Beachen et al., 2002). However, few evidence has indicated a dose-335 
dependent reduction in post-exercise HR at 1 and 2h (Tham et al. 1993). 336 
The present findings suggest that combined α/β-adrenergic blockade during moderate-337 
intensity exercise does not influence appetite/satiety sensations or subsequent food intake 338 
following exercise in obese women. The changes in blood glucose and plasma FFA suggest 339 
that the 100mg of α/β adrenergic blocker were sufficient to induce β-adrenergic blockade. 340 
Labetalol was chosen as a safe and well understood α/β blocker, however, it has greater 341 
affinity for β- than α-adrenoceptors (MacCarthy et al., 1983). For this reason, any conclusions 342 
with respect to α- adrenoceptor blockade should be drawn with caution. Labetalol decreased 343 
circulating FFA and increased glucose concentrations, which indicate inhibition of 344 
catecholamine-stimulated lipolysis and confirm the primarily β-adrenoceptor blockade. There 345 
is no simple way to know if α-blockade was adequate. There is evidence which attributes the 346 
anorexigenic effect of catecholamines to α-adrenoceptors in the brain (Wellman et al. 1993). 347 
It is this effect that a popular class of antiobesity drugs exploit to reduce eating behaviour 348 
(e.g. sibutramine) by blocking noradrenaline (NA) reuptake through activation of brain α1-349 
adrenoceptor receptors (Lean, 2001).  350 
 351 
Study limitationsThe monitoring period of appetite response was relatively brief in our 352 
study. According to recent findings changes in appetite hormones could emerge over the 353 
following 24 hrs (King et 354 
al., 2015). Determining the energy intake response might also require multiple ad libitum 355 
meals, rather than single feeding episodes (Deighton et al., 2014).  In our study, all women 356 
were premenopausal but menstrual cycle was not controlled for in the study design to account 357 
for the perceived confounding effect of the menstrual cycle on appetite sensations, appetite-358 
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regulating hormones and energy intake (Brennan et al. 2009). However, we did not find any 359 
differences in appetite responses and energy intake between the interventions which could 360 
have been confounded by cyclical changes in sex hormones in our women. 361 
 362 
Conclusions 363 
In conclusion, neither inhibition of exercise-induced adrenergic activity by combined 364 
alpha/beta adrenergic blockade, nor moderate increases in adrenergic activity induced by 365 
intravenous adrenaline infusion, significantly affected acute appetite ratings or ad-libitum 366 
intake in obese premenopausal women. Testing with a more potent α-blockade may be 367 
necessary to trigger a detectable effect and elucidate the role of adrenergic activity in 368 
exercise-induced anorexia. In this way we could conclude with complete confidence that the 369 
observed anorexic effect of exercise on appetite in obese women is not mediated by increased 370 
adrenergic activity. Finally, to definitively exclude sympathetic system involvement in 371 
exercise-related appetite regulation, the effects of more selective α-adrenergic stimulation on 372 
leptin-mediated appetite sensitivity after exercise should be investigated.  373 
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Table 1. Subject characteristics, n = 10. 
Age (years) 50.3 ± 1.9 
Weight (kg) 90.2 ± 5.2 
Height (cm) 158.0 ± 0.02 
BMI (kg.m-2) 36.0 ± 4.1 
Waist circumference (cm) 104.8 ± 4.1 
Hip circumference (cm) 115.2 ± 3.1 
Fat mass (%) predicted by waist 47.7 ± 1.7 
Systolic Blood Pressure (mmHg) 129.6 ± 2.4 
Diastolic Blood Pressure (mmHg) 89.2 ± 1.4 
Values are mean ± SEM.  
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
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Data are shown as mean ± SEM; no significant differences between interventions  in both  EXP-1 and EXP-2 (paired t-test).   
Table 2. Buffet style dinner intake subsequent to all interventions.     
Dietary intake Exercise  
plus placebo, n=10 
Exercise 
plus α/β blocker, n=10 
p-Value    Adrenaline 
infusion, n=9 
 
Saline  
infusion, n=9 
p-
Value 
Energy intake (kcal) 812.7 ± 75.9 899.9 ± 64.7 0.23 1023.3 ± 81.2 1013.2 ± 79.7 0.85 
Protein (g) 57.1 ± 6.6 59.2 ± 5.5 0.48 67.8 ± 7.6 65.2 ± 6.1 0.43 
Protein (%) 28 ± 1.6 27 ± 2.3 0.67 26.5 ±  2.2 27 ±  2.1 0.92 
Carbohydrate (g) 103.4 ± 8.2 112.8 ± 7.9  0.41 124.9 ± 9.6 120.2 ± 11.5 0.43 
Carbohydrate (%) 50 ± 2.7 48  ± 3.1 0.62 47 ± 2.8 45 ± 1.7 0.10 
Fat g 21.5 ± 2.7  26.1 ± 3.6 0.17 31.3 ± 3.4 33.1 ± 3.4 0.48 
Fat % 22 ± 1.5  25 ± 6.8  0.30 26± 1.3  28 ± 4.2 0.06 
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Values are estimated marginal means ± SEM. Analysis was conducted by GLM with repeated measures adjusted for multiple comparisons using Bonferroni corrections.  
The superscript symbol * indicates significant differences between exercise interventions (Exercise plus α/β blocker vs Exercise plus placebo: glucose 20 min p = 0.001, 80 min (after 
dinner) p < 0.001; FFA 20 min p = 0.02, 80 min (after dinner) p= 0.005).  
Table 3. Serum leptin, blood glucose, plasma free fatty acids (FFA) during the EXP-1, n=10. 
       p-Value  
 Interventions  (-60 min) (0 min) (20 min) (80 min) Time Intervention Intervention x Time  
Serum leptin (ng.ml-1) Exercise plus placebo 62.28± 6.99 65.71 ± 8.39 73.01 ± 8.45 65.65± 7.41 p = 0.0004 p = 0.694 p = 0.406 
 
 
Exercise plus α/β blocker 62.75± 7.27 63.37 ± 7.33  68.90 ± 7.5 65.24± 7.84     
Blood glucose (mmol.l-1) Exercise plus placebo  4.63 ± 0.16 4.53 ± 0.08 4.55 ± 0.09 4.52 ± 0.06 p = 0.659 p = 0.0004 p = 0.028 
 Exercise plus α/β blocker  4.59 ± 0.16 4.83 ± 0.11  4.91 ± 0.07* 4.89 ± 0.06*    
Plasma FFA (mmol.l-1) Exercise plus placebo  0.61 ± 0.13 0.65 ± 0.08 0.74 ± 0.09 0.73 ± 0.07 p = 0.866 p = 0.101 p < 0.001 
 Exercise plus α/β blocker  0.67 ± 0.11 0.59± 0.07  0.49 ± 0.06* 0.59 ± 0.06*    
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Table 4. Serum leptin, blood glucose, plasma free fatty acids (FFA), plasma adrenaline and noradrenaline (NA) concentrations during the EXP-2, n=9. 
       p-Value   
 Interventions (-60 min) (0 min) (20 min) (80 min) Time Intervention Intervention x Time 
Serum leptin (ng.ml-1) Adrenaline infusion 63.68 ± 7.77 63.20 ± 8.11 61.98 ± 8.58 67.70 ± 10.49  p = 0.068 p = 0.688 p = 0.961 
 
 
Saline infusion 65.80 ± 8.15 65.86 ± 8.07  65.31 ± 9.18 68.90 ± 7.73    
Blood glucose (mmol.l-1) 
 
Adrenaline infusion  4.79 ± 0.34 4.59 ± 0.09  4.76 ± 0.82 4.530 ± 0.07 p = 0.136 p = 0.696 p = 0.532 
 Saline infusion  5.03 ± 0.27 4.72 ± 0.06 4.60 ± 0.05 4.575 ± 0.03    
Plasma FFA (mmol.l-1) Adrenaline infusion  0.75 ± 0.15 0.84 ± 0.13 1.09 ±0.17* 0.82 ± 0.11 p = 0.010 p = 0.025 p = 0.083 
 Saline infusion  0.56 ± 0.11 0.57 ± 0.13 0.65 ± 0.15 0.70 ± 0.10    
Plasma Adrenaline (nmol.l-1) Adrenaline infusion - 0.17 ± 0.26 - -    
 Saline infusion - 0.16± 0.20 - -    
Plasma NA (nmol.l-1) Adrenaline infusion - 1.59 ± 0.19 2.32± 0.19 - p = 0.010 p = 0.063 p = 0.060 
 Saline infusion - 1.49 ± 0.26 1.61 ± 0.26 -    
Values are estimated marginal means ± SEM. Analysis was conducted by ANOVA with repeated measures adjusted for multiple comparisons using Bonferroni corrections. The 
superscript symbol * indicates significant differences between infusion trials (Adrenaline infusion vs Saline infusion: at 20 min FFA; p = 0.032) (pairwise comparisons, adjustment 
for multiple comparisons: Bonferroni). Post adrenaline infusion values of circulating adrenaline concentrations were not determined due to unresolved co-eluting peaks with 
Adrenaline. 
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Values are estimated marginal means ± SEM. Analysis was conducted by General Linear Model (GLM) with repeated measures adjusted for multiple comparisons using the 589 
Bonferroni corrections. The superscript symbol * indicates significant differences between infusion interventions (Adrenaline infusion vs Saline infusion: Perceived leg-590 
tiredness (rest p = 0.033, 5 min, 15 min and 20 min p = 0.038).  591 
   Time (min)     p-value  
 Interventions   Rest 5 10 15 20 Time Intervention Intervention 
x Time 
Heart rate (beats.min-1)      Exercice plus  
placebo 
79.83 ± 7.39 121.33 ± 9.93 132.17 ± 11.13 131.17 ± 8.87 134.33 ± 10.94 <0.001 0.572 0.146 
 Exercise plus  
α/β blocker 
86.50 ± 6.24 119.83 ± 18.43 128.17± 10.62 125.83 ± 7.56 130.67± 11.02    
 
 
Adrenaline 
infusion 
76.60 ± 5.28 75.40 ± 4.93 78.00± 4.95 81.20 ± 3.63 81.80 ± 3.99 0.016 0.098 0.053 
 Saline infusion 76.00 ± 5.21 73.50 ± 4.87 75.00 ± 6.04 74.20 ± 5.61 75.40 ± 4.53    
Perceived breathlessness 
(rating(0-20))       
Exercise plus  
placebo 
7.83± 0.70 9.83 ± 0.54 11.17± 0.65 11.50 ± 0.81 12.33 ± 0.53 <0.001 0.468 0.758 
 Exercise plus  
α/β blocker 
7.17 ± 0.17 10.00 ± 0.76 11.00 ± 0.67 12.17 ± 0.48 12.33 ± 0.33    
 
 
Adrenaline 
infusion 
8.29 ± 0.78 7.71 ± 0.64 8.00 ± 0.66 7.71 ± 0.64 7.71 ± 0.644 0.461 0.458 0.394 
 Saline infusion 7.86 ± 0.63 8.00 ± 0.66 8.00 ± 0.66 7.86 ± 0.63 7.857 ±0.634    
Perceived leg-tiredness 
(rating (0-20)) 
Exercise plus  
placebo 
7.33 ± 0.42 10.67 ± 0.67 11.50 ± 0.56 12.33 ± 0.72 12.50 ± 0.34 <0.001 0.475 0.490 
 Exercise plus  
α/β blocker 
8.00 ± 0.63 10.33 ± 0.61 11.83 ± 0.83 12.83 ± 0.60 13.33 ± 0.76    
 Adrenaline 
infusion 
7.50 ± 0.46 7.50 ± 0.46 7.75 ± 0.62 7.63 ± 0.53 7.63 ± 0.53 0.252 0.039 0.732 
 Saline infusion 8.50 ±0.66* 8.75 ±0.73* 8.75 ± 0.73 8.75 ± 0.73* 8.75 ± 0.73*    
Table 5. Heart rate, perceived breathlessness and leg-tiredness during the exercise and infusion interventions in both experiments.  
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Table 6. Gas exchange, energy expenditure and substrate oxidation in EXP 1 (at rest and during 20min of exercise) and in EXP 2 (at rest and during 20 min of 592 
adrenaline/saline infusion) 593 
 Trials Rest 20 min intervention  
VO2 (L.min-1) Exercise plus placebo 0.3 ± 0.04 1.4 ± 0.3 
 Exercise plus α/β blocker 0.3 ± 0.06 1.3 ± 0.4 
 Saline infusion  0.2 ± 0.09 0.3 ± 0.05 
 Adrenaline infusion 0.3 ± 0.06 0.3 ± 0.05 
VCO2 (L.min-1) Exercise plus placebo 0.2 ± 0.06 1.1 ± 0.2 
 Exercise plus α/β blocker 0.2 ± 0.07 1.1 ± 0.3 
 Saline infusion  0.2 ± 0.07 0.2 ± 0.04 
 Adrenaline infusion 0.2 ± 0.05 0.2 ± 0.03 
Energy Expenditure (kcal·min-1) Exercise plus placebo 1.3 ± 0.1 6.8 ± 1.5 
 Exercise plus α/β blocker 
1.3 ± 0.3 
6.4 ± 2.0 
 Saline infusion  1.1 ± 0.4 1.2 ± 0.2 
 Adrenaline infusion 1.3 ± 0.3 
 
1.4 ± 0.2 
CHO oxidation (g·min-1) Exercise plus placebo 0.08 ± 0.33 0.58 ± 0.45 
 Exercise plus α/β blocker 0.10 ± 0.15 0.55 ± 0.27 
 Saline infusion  0.06 ± 0.15 0.07 ± 0.09 
 Adrenaline infusion 0.08 ± 0.12 0.03 ± 0.15 
Fat oxidation (g·min-1) Exercise plus placebo 0.10 ± 0.13 0.48 ± 0.21 
 Exercise plus α/β blocker 0.09 ± 0.04 0.45 ± 0.15 
 Saline infusion  0.10 ± 0.06 0.15 ± 0.07 
 Adrenaline infusion 0.10 ± 0.06 0.14 ± 0.07 
Values are estimated marginal means ± SEM. No significant differences were found between trials in EXP-1 or EXP-2   594 
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Table A1. CONSORT Checklist of information about the present randomised controlled study. 595 
 596 
Section/Topic 
Item 
No Checklist item 
Reported  
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 1 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 2 
2b Specific objectives or hypotheses 2 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 3 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons 3 
Participants 4a Eligibility criteria for participants 3 
4b Settings and locations where the data were collected 3 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually 
administered 
 
3,4 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 3,4,5 
6b Any changes to trial outcomes after the trial commenced, with reasons NA 
Sample size 7a How sample size was determined Pages 1 & 4 
7b When applicable, explanation of any interim analyses and stopping guidelines NA 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 3 
8b Type of randomisation; details of any restriction (such as blocking and block size) 3 
 Allocation 
concealment 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps 
taken to conceal the sequence until interventions were assigned 
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7 
 
mechanism 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions 3 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) 
and how 
3 
11b If relevant, description of the similarity of interventions NA 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 5 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 5 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the 
primary outcome 
 Figure S1- 
Supplementary 
material 
13b For each group, losses and exclusions after randomisation, together with reasons Figure S1 
Recruitment 14a Dates defining the periods of recruitment and follow-up NA 
14b Why the trial ended or was stopped NA 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Pg.3 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned 
groups 
FS1 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% 
confidence interval) 
6-11 
Tables 2-4 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended NA 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from 
exploratory 
NA 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) NA 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 12-14 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 12-14 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 12-14 
8 
 
Other information  
Registration 23 Registration number and name of trial registry 3 
Protocol 24 Where the full trial protocol can be accessed, if available NA 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders                   14 
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 Figure S1. Participant flow diagram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=24 ) 
Excluded (n=14) 
♦   Not meeting inclusion criteria (n= 14 ) 
 
 
Allocated in EXP-1 (n= 10) 
♦ Received allocated exercise intervention (n= 10 ) 
Allocated in EXP-2 (n= 9) 
♦ Received allocated infusion intervention (n= 9)  
 
 
Analysed in EXP-1 (n= 10), EXP-2 (n= 9) 
 
 
Allocation 
Analysis 
Randomized in full protocol of EXP-1 and 
EXP-2 (n=10) 
Enrollment 
7-days wash out  
Dropped after the EXP-1  (n= 1) 
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